SLS
HealthcareSELLAS Life Sciences Group, Inc. · Biotechnology · $1B
What is SELLAS Life Sciences Group, Inc.?
SELLAS Life Sciences Group is a late-stage biopharmaceutical company focused on developing novel cancer immunotherapies. Headquartered in New York City, it targets difficult-to-treat cancer indications with peptide-based therapeutic candidates currently in active clinical trials.
SELLAS generates no commercial revenue at this stage — its business model centers on advancing clinical-stage cancer immunotherapy candidates through trials toward potential regulatory approval. Its lead asset, galinpepimut-S (GPS), targets the Wilms tumor 1 antigen and is being studied in acute myeloid leukemia and ovarian cancer. A second candidate, nelipepimut-S, targets HER2 and is in trials for early-stage breast cancer. A collaboration with Merck evaluates GPS alongside pembrolizumab across multiple cancer types.
SELLAS was founded in 2008 and is headquartered in New York City, New York.
- Galinpepimut-S (GPS) — Phase III immunotherapy for acute myeloid leukemia
- GPS in Phase 1/2 trials for ovarian cancer
- Nelipepimut-S — Phase 2b HER2-targeting therapy for early-stage breast cancer
- Merck collaboration evaluating GPS with pembrolizumab across five cancer indications
Is SLS a Good Stock to Buy?
UQS Score rates SLS as Poor overall, reflecting significant challenges across most of its five scoring pillars.
Among the five pillars, Risk registers as Neutral — a relative bright spot suggesting the company's near-term operational risk profile is not at the most extreme end for clinical-stage biotechs. This is the only pillar that avoids a Weak or Elevated designation.
Quality, Moat, and Growth all score Weak, consistent with a pre-revenue company that has no durable competitive advantages established yet. Valuation is rated Elevated, meaning the current market price appears high relative to the company's fundamental profile.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SLS pay dividends?
No — SELLAS Life Sciences Group, Inc. does not currently pay a dividend.
SELLAS does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding ongoing clinical trials and research operations. Investors in SLS are taking a development-stage bet rather than seeking income, and a dividend is unlikely until the company achieves commercial revenue.
When does SLS report earnings?
SELLAS Life Sciences reports financial results on a quarterly cadence, standard for US-listed public companies.
As a pre-revenue clinical-stage company, SELLAS quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than revenue or profit metrics. Investors should monitor trial readouts and partnership updates as the key value-driving events.
For the most recent quarter's results and upcoming reporting dates, visit SELLAS Life Sciences' investor relations page directly.
SLS Price History
-57.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in SELLAS Life Sciences Group, Inc.?
Based on SELLAS Life Sciences Group, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SLS Long-term Outlook
The fundamental outlook for SLS is shaped by its clinical pipeline rather than near-term financial performance. With Growth rated Weak and Valuation rated Elevated, the risk-reward profile demands careful consideration. Positive Phase III data for GPS in acute myeloid leukemia would represent the most significant potential catalyst, while continued cash consumption without a commercial product remains the central challenge.
Growth drivers
- Phase III readout for galinpepimut-S in acute myeloid leukemia
- Expanded Merck collaboration data across multiple cancer indications
- Potential regulatory milestones for nelipepimut-S in breast cancer
Key risks
- Clinical trial failure or delays across any lead candidate
- Ongoing cash burn with no commercial revenue to offset expenses
- Elevated valuation leaves limited margin of safety if trial results disappoint
SLS vs Peers
SELLAS operates in a crowded clinical-stage oncology space alongside several small-cap peers pursuing similar immunotherapy and targeted cancer treatment approaches.
Gyre Therapeutics focuses on fibrosis and metabolic disease rather than pure oncology immunotherapy, giving it a distinct therapeutic focus from SELLAS.
Jade Biosciences is an early-stage oncology company building its pipeline from an earlier development phase than SELLAS's late-stage GPS program.
BridgeBio Oncology targets oncogenic driver mutations, differentiating its precision medicine approach from SELLAS's antigen-targeting immunotherapy strategy.
Frequently Asked Questions
What does SELLAS Life Sciences do?
SELLAS Life Sciences is a clinical-stage biopharmaceutical company developing cancer immunotherapies. Its lead program, galinpepimut-S, targets the Wilms tumor 1 antigen in leukemia and ovarian cancer. A second asset, nelipepimut-S, targets HER2 in breast cancer. The company has no commercial products and generates no product revenue at this time.
Does SLS pay dividends?
No, SELLAS does not pay a dividend. As a pre-revenue clinical-stage biotech, the company directs all capital toward funding its clinical trials. A dividend is not expected until the company achieves commercial-stage revenue, which depends on successful trial outcomes and regulatory approvals.
When does SLS report earnings?
SELLAS reports financial results quarterly, in line with standard US public company requirements. Because it is pre-revenue, reports focus on operating expenses and cash position rather than sales figures. Check the company's investor relations page for the most current reporting schedule and recent filings.
Is SLS a good stock to buy?
UQS Score rates SLS as Poor, reflecting Weak scores across Quality, Moat, and Growth pillars, alongside an Elevated Valuation rating. The only relative strength is a Neutral Risk score. This profile suggests a high-risk, speculative investment dependent on clinical trial success. Investors should review the full pillar breakdown before drawing conclusions.
Is SLS overvalued?
UQS Score's Valuation pillar for SLS is rated Elevated, indicating the current market price appears high relative to the company's fundamental profile. For a pre-revenue biotech, valuation is inherently speculative and tied to pipeline probability. The complete valuation analysis is available to Pro members on UQS Score.
How does SLS compare to its competitors?
SELLAS competes in the clinical-stage oncology space alongside peers such as Gyre Therapeutics, Jade Biosciences, and BridgeBio Oncology Therapeutics. Each pursues different therapeutic targets and development stages. UQS Score provides side-by-side pillar comparisons for Pro members to evaluate these companies on Quality, Growth, Moat, Risk, and Valuation.
What is SLS's market cap bracket?
SELLAS Life Sciences is classified as a small-cap company. Small-cap clinical-stage biotechs typically carry higher volatility and liquidity risk than larger peers, and their valuations are heavily influenced by binary clinical trial outcomes rather than steady financial performance.
Who founded SELLAS Life Sciences?
SELLAS Life Sciences was founded in 2008. Detailed founding history, including founder names and the company's evolution from its earlier corporate identity, is publicly available through the company's official filings and investor relations materials.
Is SLS a long-term quality investment?
As a long-term quality indicator, UQS Score rates SLS as Poor. Weak scores in Quality, Moat, and Growth reflect the absence of established competitive advantages and a pre-revenue business model. Long-term quality typically requires durable earnings power and a defensible market position — neither of which SELLAS has demonstrated yet.
What is the main competitive advantage of SELLAS Life Sciences?
SELLAS's potential differentiation lies in its peptide-based immunotherapy platform targeting specific cancer antigens, particularly the Wilms tumor 1 target addressed by GPS. Its collaboration with Merck adds credibility to the GPS program. However, UQS Score rates SELLAS's Moat as Weak, reflecting that no durable competitive advantage has been established at this clinical stage.
What sector does SLS belong to?
SLS belongs to the Healthcare sector, specifically within the biopharmaceutical and clinical-stage drug development industry. Investors can explore other [Healthcare sector stocks scored by UQS](/sector/healthcare) to compare quality profiles across the space.
Unlock Full SLS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores
- ✓Access complete financial metrics and trend data
- ✓Compare SLS side-by-side with oncology peers
- ✓See the full Risk and Valuation breakdown
- ✓Get alerts when SLS pillar scores change
- ✓Explore the complete analyst-grade quality report
Pro Analysis
SLS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 12.8 | 0.0 | 8.0 | 18.5 | 47.1 | 0.0 | +3.9 |
| May 9, 2026 | 8.9 | 0.0 | 8.0 | 0.0 | 46.2 | 0.0 | -3.9 |
| Apr 22, 2026 | 12.8 | 0.0 | 8.0 | 18.5 | 47.1 | 0.0 | -0.9 |
| Apr 2, 2026 | 13.7 | 0.0 | 8.0 | 23.1 | 47.1 | 0.0 | — |
SLS — Pillar Breakdown
Quality
— 0.0/100 (25%)SELLAS Life Sciences Group, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)SELLAS Life Sciences Group, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)SELLAS Life Sciences Group, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)SELLAS Life Sciences Group, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 8/100 (25%)SELLAS Life Sciences Group, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SLS.
Score Composition
Financial Data
More Stock Analysis
How is the SLS UQS Score Calculated?
The UQS (Unified Quality Score) for SELLAS Life Sciences Group, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses SELLAS Life Sciences Group, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether SELLAS Life Sciences Group, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.